Title: Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial
Authors: Baselga, José ×
Bradbury, Ian
Eidtmann, Holger
Di Cosimo, Serena
de Azambuja, Evandro
Aura, Claudia
Gómez, Henry
Dinh, Phuong
Fauria, Karine
Van Dooren, Veerle
Aktan, Gursel
Goldhirsch, Aron
Chang, Tsai-Wang
Horváth, Zsolt
Coccia-Portugal, Maria
Domont, Julien
Tseng, Ling-Min
Kunz, Georg
Sohn, Joo Hyuk
Semiglazov, Vladimir
Lerzo, Guillermo
Palacova, Marketa
Probachai, Volodymyr
Pusztai, Lajos
Untch, Michael
Gelber, Richard D
Piccart-Gebhart, Martine
NeoALTTO Study Team #
Contributors: Wildiers, Hans
Issue Date: Feb-2012
Publisher: The Lancet Publishing Group
Series Title: The Lancet vol:379 issue:9816 pages:633-40
Article number: 10.1016/S0140-6736(11)61847-3
Abstract: The anti-HER2 monoclonal antibody trastuzumab and the tyrosine kinase inhibitor lapatinib have complementary mechanisms of action and synergistic antitumour activity in models of HER2-overexpressing breast cancer. We argue that the two anti-HER2 agents given together would be better than single-agent therapy.
ISSN: 0140-6736
Publication status: published
KU Leuven publication type: IT
Appears in Collections:Laboratory of Experimental Oncology
× corresponding author
# (joint) last author

Files in This Item:

There are no files associated with this item.

Request a copy


All items in Lirias are protected by copyright, with all rights reserved.

© Web of science